The signifi cance of nonalcoholic fatty liver disease (NAFLD) among patients with diabetes is unknown. We sought to determine whether a diagnosis of NAFLD infl uenced mortality among a community-based cohort of patients with type II diabetes mellitus.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is a common diagnosis in clinical practice of several medical specialties ( 1 ) . In the United States, 1 in 3 adults and 1 in 10 children or adolescents suff er from NAFLD ( 2, 3 ) . Similarly, the prevalence of diabetes mellitus has reached proportions observed never before, with 8 % of individuals in the United States aff ected with the disease ( 4 ) . In addition, it has recently been estimated that people born in the year 2000 have a 33 -38 % lifetime risk of developing diabetes ( 5 ) .
Th e pathogenesis of diabetes and NAFLD are intimately related to insulin resistance and hyperinsulinemia ( 6 ) . Consequently, diabetes mellitus is frequently observed in patients with NAFLD, being present in 18 -45 % of cases ( 3, 7, 8 ) . Similarly, NAFLD is common among patients with type II diabetes with the prevalence ranging between 49 and 75 % ( 9 -11 ).
Concomitant diabetes mellitus among patients with NAFLD is associated with more severe infl ammation and fi brosis on liver biopsy and with a more rapid fi brosis progression ( 12 -14 ) . In addition, diabetes is recognized to increase the risk of cirrhosis-related Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort Study LIVER complications such as hepatocellular carcinoma ( 15 ) . Furthermore, the presence of diabetes mellitus increases the risk for liver-related death and overall death among patients with NAFLD ( 8, 16 ) . Direct upregulation of fi brogenic growth factors by hyperinsulinemia and hyperglycemia ( 17 ) , along with changes in adipocytokine levels that accompany diabetes, such as increased tumor necrosis factor-α and reduced adiponectin levels ( 18 ) , may have signifi cant roles in contributing to liver damage and development of complications in NAFLD patients who suff er from diabetes.
Although it is clear that diabetes mellitus is of prognostic signifi cance among patients with NAFLD ( 8, 10, 14, 16 ) , it is not clear whether NAFLD is of prognostic signifi cance among patients with diabetes mellitus. In a large community-based study, we have recently shown that NAFLD is independently associated with an increased risk of all-cause mortality compared with the general population of the same age and gender ( 16 ) . Th is higher mortality among patients with NAFLD was subsequently confi rmed in a Swedish study of patients presenting with elevated liver enzymes due to NAFLD ( 19 ) . Th e prevalence of diabetes mellitus in the Swedish study was 37.5 % ; the prevalence of diabetes in our community cohort with NAFLD was 26 % as compared with a prevalence of 5 % in the same community population ( 20 ) . Th e comparative control group in both series was matched only by age and gender to the NAFLD cases (16, 19) , and thus, it remains uncertain whether the higher mortality in the NAFLD group in both studies was because of this higher prevalence of diabetes or NAFLD itself. We therefore performed a longitudinal community-based cohort study of subjects with diabetes mellitus to examine whether the presence of NAFLD is associated with an increased risk of overall mortality and cause-specifi c mortality, compared with a control group who had been tested for liver abnormalities but were negative for NAFLD.
METHODS
Th e study was approved by the institutional review boards of the Mayo Clinic and Olmsted Medical Center, and all participants provided permission for their medical records to be used for research.
Study setting
Th e study population was derived from residents of Olmsted County located in Southeastern Minnesota. Population-based epidemiological research can be conducted in Olmsted County, Minnesota, because medical care is virtually self-contained within the community and there are only few healthcare providers. Each of these providers uses a unit medical record, whereby all inpatient and outpatient medical information for patients is accumulated in a single record. All diagnoses made in outpatient offi ce or clinic visits, hospitalizations, emergency room visits, nursing home care, surgical procedures, autopsies, and death certifi cates are indexed and retrievable through the Rochester Epidemiology Project (REP) ( 21, 22 ) . Each year, 87 % of Olmsted County residents are seen at least once by a health care professional and, in any given 4-year period, at least one health encounter is recorded in over 95 % of county residents ( 22 ) . Th us, the REP makes it possible to identify patients with certain characteristics (such as diabetes) and follow them longitudinally assessing long-term outcomes such as mortality and causes of death.
Data ascertainment
Patients with diabetes mellitus were identifi ed using the resources of the REP and the Mayo Clinic Laboratory Information System (MLIS). Th e MLIS is a database of all blood test results performed by the Mayo Clinic Laboratories since the year 1983. Th e database includes information on the geographical residence of patients, allowing categorization of blood results by County.
Patients with diabetes mellitus were identifi ed fi rst by searching the REP master diagnostic index using Patients with a concomitant diagnosis of NAFLD were identifi ed using HICDA codes for fatty liver, hepatic steatosis or steatohepatitis (5710-42-42, 5710-43-1, 5710-43-0, 5470-42-0 to 4, and 2790-44-1). From the cohort of patients identifi ed as having diabetes, but not concomitant NAFLD, a random 9.5 % sample subset of 684 patients were selected aft er stratifi cation by time period of diagnosis (that is, during 1980 -85, 1986 -90, 1991 -95, and 1996 -1999) to ensure similar periods of follow-up as the NAFLD patients. Medical records of patients identifi ed were extensively reviewed to ensure that patients fulfi lled the case defi nitions (see below). Diabetes case ascertainment was over a 20-year period from 1 January 1980 to 31 December 1999. As we wished to examine whether a diagnosis of NAFLD was a risk factor for mortality among patients with diabetes mellitus, we included patients diagnosed with diabetes for the fi rst time on or aft er 1 January 1980. Th e year 1980 was chosen, as NAFLD was better defi ned as a disease entity in this year ( 23 ) . Th e date 31 December 1999 was chosen to allow a 20-year ascertainment period. Patient follow-up was extended up to 1 January 2005.
Case defi nitions
Th e diagnosis of diabetes required a fasting blood glucose level ≥ 126 mg / dl or a random glucose ≥ 200 mg / dl in presence of symptoms, as recommended by the American Diabetes Association ( 24 ) . Date of diagnosis was from date of the fi rst elevated fasting glucose level leading to the diagnosis of diabetes. Patients were excluded if they had type I diabetes or secondary causes for hyperglycemia (nonfasting, glucocorticoids, acute illness, or Cushing ' s disease).
Th e diagnosis of NAFLD required confi rmation of hepatic steatosis by either abdominal imaging (ultrasound, computed tomography, or magnetic resonance imaging) or by liver biopsy. Patients
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with secondary causes for hepatic steatosis were excluded, as were patients with evidence of other liver diseases on clinical history or examination, laboratory studies, imaging, or biopsy. Patients at risk of viral hepatitis due to intravenous drug use or blood product transfusion before the year 1992 were excluded if they had not had hepatitis B or C serology performed aft er their exposure. Information on alcohol consumption (type, amount, frequency, duration, as well as alcohol abuse screening questions) was collected prospectively as part of the medical record, by a patient history form fi lled out by the patient and reviewed by a nurse and physician at each visit. Patients with a daily ethanol consumption > 20 grams were excluded.
Patients with diabetes, but not NAFLD, were required to have (i) a minimum of three sets of normal liver enzymes (alanine aminotransferase < 29 IU / ml for females, < 45 IU / ml for males, aspartate aminotransferase < 31 IU / ml for males and females, bilirubin < 1.3 mg / dl, albumin < 3.5 gm / l, alkaline phosphatase less than age and gender-specifi c ranges of the MLIS); (ii) normal liver enzymes at time of diabetes diagnosis and at any time measured during follow-up; and (iii) absence of steatosis in imaging, if abdominal imaging studies were performed for any indication.
A total of 7,171 diabetics without NAFLD were identifi ed from HICDA coding and the MILS over the study time period (that is, during 1980 -1999). From these subjects, a subset of 684 patients was randomly selected aft er stratifi cation by time period of diagnosis and their medical records were extensively reviewed to verify whether they fulfi lled the inclusion criteria. Reasons for exclusion from the study were date of diagnosis of diabetes before the year 1980 ( n = 66), type I diabetes ( n = 41), gestational diabetes ( n = 6), hyperglycemia due to medications or illness ( n = 15), hyperglycemia not within diabetic range ( n = 36), non-NAFLD liver disease ( n = 9), initial diabetes diagnosis outside of Olmsted County or non-County residents ( n = 53), unexplained elevated liver tests ( n = 109), less than three sets of liver enzymes measured ( n = 45), or evidence of hepatic steatosis on imaging aft er the year 1999 or at post-mortem ( n = 83). Th ese exclusions left a total of 221 / 684 (32 % ) patients who fulfi lled the inclusion criteria for diabetics without NAFLD. Extending this proportion to the 7,171 subjects identifi ed by HICDA coding and the MLIS as having diabetes without NAFLD, would mean that ~ 2,295 (32 % ) would fulfi ll our study criteria as having confi rmed type II diabetes mellitus diagnosed in Olmsted County between 1980 and 1999 in the absence of NAFLD or other liver disease. A total of 116 individuals fulfi lling the same inclusion criteria for diagnosis of diabetes, geographical location, and time period were identifi ed as having concomitant NAFLD by HICDA coding. Th ree subjects were previously excluded owing to diabetes being diagnosed aft er the year 1999.
Th us, 337 subjects with type II diabetes (221 without NAFLD and 116 with NAFLD) comprised our study population. Th ese 337 patients underwent a mean ( ± s.d.) follow-up of 10.5 ( ± 5.2) years (range 0.1 -25 years). Of them, 116 patients were diagnosed with NAFLD 0.9 ( ± 4.6) years (range of − 9.9 to 16.1 years) aft er their initial diagnosis of diabetes mellitus. Th e other 221 patients with type II diabetes mellitus, who did not develop NAFLD, constitute the control group.
Data abstraction
Th e following information was abstracted from the medical records at date of diagnosis of diabetes; age, gender, race, diabetes treatment required within 3 months of diagnosis, past medical history of hyperlipidemia, hypertension, ischemic heart disease, cerebrovascular disease, chronic renal failure, height, weight, blood pressure, medications, laboratory data (bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, albumin, fasting glucose, glycosylated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, and triglyceride level). In addition, for patients with diabetes but not NAFLD, serial liver tests aft er time of diagnosis of diabetes and any hepatic imaging studies were recorded. Follow-up and cause of death were obtained from medical records and death certifi cates.
Statistical analysis
Th e results are presented as number and percent or as mean and standard deviation. Baseline characteristics of patients with or without NAFLD are compared using student ' s t -test, χ 2 tables, or Fisher ' s exact test when appropriate. Cox proportional hazards modeling was used to evaluate overall mortality. Co-morbidities diagnosed at the time of diabetes diagnosis were entered into separate Cox proportional hazard models aft er adjustment for age, gender, and date of diabetes diagnosis (duration of diabetes). NAFLD was treated as a time-dependent covariate from date of diabetes diagnosis. To assess the independent eff ect of NAFLD on mortality, variables that were considered to be potential confounders were entered into a multivariable Cox proportional hazard model. Two-way interactions between NAFLD and age, gender, date of diabetes diagnosis, as well as age and gender were performed with no signifi cant interaction found at the α = 0.05 level. Analysis was performed using SAS Release 8.2 (SAS Institute, Cary, NC).
RESULTS
Patients characteristics
A total of 337 subjects with type II diabetes mellitus were identifi ed; 116 had a confi rmed diagnosis of NAFLD either before the diagnosis of diabetes or during follow-up, and 221 were without a diagnosis of NAFLD. Subjects without NAFLD were signifi cantly more likely to be male, older, and ex or current smokers, compared with those who developed NAFLD ( Table 1 ) . Subjects with NAFLD were more likely to be obese and correspondingly had a higher mean body mass index. Th ere was no signifi cant diff erence in prevalence of other features of the metabolic syndrome including hypertension, hypertriglyceridemia, or low high-density lipoprotein cholesterol levels. In addition, the prevalence of ischemic heart disease or cerebrovascular disease either alone or in combination was not signifi cantly diff erent between the two groups. Similarly, there was no diff erence in the apparent severity of diabetes with HbA1c values similar between the two groups. Further, the treatment regimens for diabetes and use of medication for hypertension and hyperlipidemia were similar between the two groups.
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Of the 116 diabetic subjects diagnosed with NAFLD, 114 underwent abdominal imaging studies (85 ultrasound and 29 computed tomography) and 26 had a liver biopsy performed. As expected, subjects with NAFLD had higher levels of alanine aminotransferase and aspartate aminotransferase at time of diagnosis of diabetes compared with those without NAFLD.
Follow-up
Th e mean ( ± s.d.) duration of follow-up of the total cohort from time of diagnosis of diabetes was 10.9. ( ± 5.2) years with a range of 0.1 -25.0 years. Th e diagnosis of NAFLD followed the initial diagnosis of diabetes aft er a mean of 0.9 ( ± 4.6) years with a range of − 9.9 to 16.1 years in the 116 subjects. Th e average follow-up from initial diagnosis of diabetes was shorter among subjects who developed NAFLD than those who did not (9.2 ± 5.2 years vs. 11.7 ± 5.0 years, P < 0.001) due to higher mortality rate in the NAFLD group.
Causes of death
Overall, 99 (29 % ) subjects died during follow-up; 27 with NAFLD and 72 without NAFLD ( Table 2 ) . Th e most common causes of death were malignancy in patients with NAFLD and ischemic heart disease in patients without NAFLD. Both malignancy and ischemic heart disease accounted for over half of all deaths in both groups. Among diabetic patients with NAFLD, liver complications and heart disease were the second leading causes of death, each accounting for 19 % of all deaths in this group. Of the liver-related deaths, one patient died from liver failure secondary to cirrhosis complicated by hepatocellular carcinoma; the other patients died from liver failure ( n = 3) and variceal bleeding ( n = 1). No liverrelated deaths were seen in the group without NAFLD.
The Impact of NAFLD on Mortality
Th e eff ect of NAFLD and other co-morbidities on mortality among patients with diabetes mellitus, were examined in separate Cox proportional hazards models aft er adjustment for age, gender, and date of diagnosis of diabetes (that is, duration of follow-up) ( Table 3 ). NAFLD was signifi cantly associated with an increased risk of death (hazard ratio (HR) 1.7, 95 % confi dence interval (CI) 1.04 -2.7). Means of diagnosis for NAFLD was associated with a diff erence in mortality, with those who underwent liver biopsy having a higher risk of death ( P < 0.001) with a HR 
Significance of NAFLD in Diabetes
LIVER
hypertension did not aff ect mortality and did not change the signifi cance of the association of NAFLD with mortality.
To determine whether patients with NAFLD had a greater risk of a specifi c cause of death, multivariable Cox proportional hazards modeling was used with the end points of death due to heart disease, cardiovascular disease (combination of death from ischemic heart disease and cerebrovascular disease), malignancy, and liver-related death. Aft er adjustment for age, gender, obesity, and date of diabetes diagnosis, patients with NAFLD were at a borderline signifi cantly greater risk of death from malignancy (HR 2.3, 95 % CI 0.9 -5.9, P = 0.09). Th ere was no increase in risk of death from heart disease (HR 1.1, 95 % CI 0.4 -3.1, P = 0.89) or cardiovascular (that is, heart plus cerebrovascular) disease (HR 0.9, 95 % CI 0.3 -2.4, P = 0.81). Th e HR for liver-related death was not able to be calculated as no subjects without NAFLD died from liver-related causes.
DISCUSSION
As NAFLD is common and generally asymptomatic in patients with diabetes mellitus, the clinical signifi cance of NAFLD has traditionally been overlooked. In this study, we have shown that presence of NAFLD is associated with an increased overall mortality and with a signifi cantly higher mortality due to liver disease and malignancy in patients with type II diabetes. Importantly, this association is independent of classical risk factors and several of 5.3 (95 % CI 2.4 -11.5) that remained virtually unchanged aft er adjustment for age, gender, and date of diabetes diagnosis (HR 5.3, 95 % CI, 2.2 -12.9, P < 0.001). No patient died from biopsy-related complications. In addition, a history of ischemic heart disease or cerebrovascular disease was also associated with an increased risk of death.
To assess whether NAFLD was independently associated with an increased risk of all-cause mortality, potential confounders were entered into a multivariable Cox proportional hazard model ( Table 4 ) . NAFLD remained an independent risk factor for mortality when controlling for all other potential confounders. Age, duration of diabetes, earlier malignancy, cerebrovascular disease, and ischemic heart disease were also independently associated with risk of death. Treatment regimens for diabetes (oral hypoglycemic or insulin) or the use of medications for hyperlipidemia or BMI, body mass index; CI, confi dence interval; CVD, cerebrovascular disease; HR, hazards ratio; IHD, ischemic heart disease; NALFD, nonalcoholic fatty liver disease. Hypertension is defi ned as > 135 / 85 or taking anti-hypertensive medication; obesity is defi ned as BMI ≥ 30 kg / m 2 ; hyperlipidemia is defi ned as elevated triglycerides ( ≥ 150 mg / dl), or low high-density lipoprotein (HDL ≥ 40 mg / dl for men, ≥ 50 mg / dl for women), or taking lipid-lowering medication. ; hyperlipidemia is defi ned as elevated triglycerides ( ≥ 150 mg / dl), or low high-density lipoprotein (HDL ≥ 40 mg / dl for men, ≥ 50 mg / dl for women), or taking lipid-lowering medication.
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features of the metabolic syndrome. Subjects with diabetes but not NAFLD were signifi cantly older and had a longer period of follow-up, potentially favoring an increased risk of death in this group. However, aft er adjustment for potential confounding variables, patients with diabetes and NAFLD had a 2.4-fold higher risk of dying as compared with patients with diabetes without NAFLD. Furthermore, the presence of NAFLD was associated with a higher risk of death than a past history of ischemic heart disease.
Liver-related death accounted for 19 % of all deaths of patients with NAFLD and diabetes, whereas no subjects without NAFLD died from liver-related causes. Th is suggests that NAFLD may be directly responsible for a proportion of the increased risk of overall death by leading to cirrhosis with fatal complications of hepatocellular carcinoma, liver failure, and variceal bleeding. Supporting this is the evidence from the Verona Diabetes Study that found the fact that the risk of death from cirrhosis among diabetics is higher than that of the general population (standardized mortality ratio = 2.5), which is greater than the risk of death from cardiovascular complications (standardized mortality ratio = 1.34) ( 25 ) .
Subjects undergoing liver biopsy had a greater HR for death, although this was unaff ected by age, gender, or date of diabetes diagnosis. Th is highlights the selection bias of non-communitybased natural history studies that rely on biopsy and the diffi culty in generalizing results from patients who have undergone liver biopsy to subjects diagnosed in the community. Patients undergoing biopsy are more likely to have signifi cant liver disease and thus have a higher risk of liver-related death. Subsequently, these cohorts will overestimate mortality rates when applied to the general community.
Patients with NAFLD also had a trend toward a greater risk of dying from malignancy compared with subjects without NAFLD. A Danish population-based study found an increased risk of hepatic and nonhepatic-related malignancy among 1,800 subjects discharged from hospital with a diagnosis of NAFLD compared with the general population ( 5 ) . Th e potential mechanisms through which NAFLD may lead to an increased risk of malignancy are unclear. NAFLD-associated cirrhosis may be complicated by hepatocellular carcinoma and this occurred in one patient, although this patient was included among the liver-related deaths rather than deaths secondary to malignancy. Subjects with NAFLD were signifi cantly heavier and had a higher prevalence of obesity than subjects without NAFLD. Obesity is an established risk factor for a range of malignancies ( 26 ) . In addition, hepatic steatosis increases hepatic insulin resistance and may exacerbate hyperinsulinemia ( 27, 28 ) . In vitro studies have shown that insulin is mitogenic to colonic mucosa ( 29 ) , and hyperinsulinemia has recently been identifi ed as an independent risk factor for colorectal malignancy at a population level ( 30 ) . Subsequently, the metabolic features associated with NAFLD may have increased the risk of malignancy in our cohort.
One of the strengths of the study is that it is communitybased and thereby minimizes the potential for selection bias and increases the ability to generalize the results to the general population. Ascertainment was maximized by using two sources to identify the potential patients -the REP and the MLIS. In addition, the REP allows evaluation of prospectively collected data and permits a long period of follow-up. Inherent in any medical record-based review is the potential for the clinician to not record or miss the diagnosis of NAFLD. We minimized this potential by also examining all biochemical results over time, with at least three liver enzymes sets determined in every patient. Although it is well recognized that liver enzymes may be normal among patients with NAFLD ( 31 ), it is also well known that liver enzymes fl uctuate over time among subjects with NAFLD ( 32 ), and thus, the chance of misclassifying an undiagnosed patient with NAFLD is minimized by taking into consideration several liver enzyme measurements. Further, any potential misclassifi cation of NAFLD subjects as non-NAFLD subjects would weaken any association in favor of no difference; therefore, the association we found is more likely to be real. It is possible that some subjects were falsely diagnosed with fatty liver; however, as ultrasound has a high ( > 90 % ) sensitivity and specifi city for the detection of fatty liver and as the diagnosis required clinical confi rmation by the managing physician, we feel this is unlikely ( 33 ) .
Recently, Targher et al. ( 34 ) have reported that 35.1 % of patients with type II diabetes seen in a single tertiary care medical center in Italy suff ered from cardiovascular disease, as defi ned by the sum of coronary heart disease and cerebral and peripheral vascular disease. Th is fi gure is higher than the 26.1 % found in our community-based study. Similarly, 77 % (1,349 / 1,749) of the total cohort of patients with type II diabetes in the Italian series ( 34 ) suff ered from NAFLD as compared with 34.4 % (116 / 337) in our series. In addition, the prevalence of several features of the metabolic syndrome was signifi cantly higher among the patients with NAFLD in the Italian series, but was not signifi cantly diff erent between patients with and without NAFLD in our series. All these diff erences between the two series can easily be explained by diff erences in the study design, leading to the inclusion of different patient populations. For instance, the Italian report ( 34 ) was a cross-sectional study with the prevalence of cardiovascular disease, NAFLD, and components of the metabolic syndrome determined at a single point in time aft er several years of suff ering from diabetes, whereas the prevalence of all those conditions in our series was determined at the time of diabetes diagnosis. Th e cumulative incidence of cardiovascular disease and the components of the metabolic syndrome, and most likely the development of NAFLD as well, is expected to increase as the duration of diabetes lengthens. In this same cohort of diabetic patients, the Italian group recently reported that presence of NAFLD was associated with a 53 % higher risk for the development of cardiovascular events within a 5-year follow-up period ( 35 ) . However, over two-thirds of the cardiovascular events recorded in that study were not fatal, and thus, the impact of NAFLD, if any, on cardiovascular-related deaths could not be estimated. Further, as other causes of death were not analyzed, the impact of NAFLD on overall mortality could not be analyzed. It is possible, however, that the cohort number in our study was not suffi cient to detect small diff erences in cardiovascular death rates between NAFLD and non-NAFLD groups.
In summary, we found that the diagnosis of NAFLD was an adverse prognostic indicator of all-cause death among patients with diabetes mellitus. Liver-related death was responsible for a substantial proportion of deaths among patients with NAFLD. Th erefore, patients with diabetes should be evaluated for evidence of NAFLD and considered for therapy. Further research is required to assess whether treatment of NAFLD leads to a reduction in liver and overall mortality rates.
